2021 and beyond with Destiny Pharma’s CEO, Neil Clark & CFO Shaun Claydon

Management of Destiny Pharma, the AIM listed infection prevention biotechnology company, offer an overview of the Company, their platform and their late stage clinical assets heading towards phase 3 trails. The team expand on the anti infective market, their COVID 19 program and the strength of their balance sheet. The Company finish with their expectations for 2022 and beyond.

#TRLS #TrellusHealth #smallcaps #smallcapsinvesting #VoxMarkets #LondonStockExchange #FinancialNews #CompanyNews #trading #investing #stocks #shares #money

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews